Ginkgo Bioworks

Headquartered in Boston, Ginkgo Bioworks is a leading end-to-end horizontal platform for cell programming, which uses biology to create innovative solutions for various applications related to several markets including agriculture, nutrition and wellness, biopharmaceutical and industrials. Its platform enables companies to design and optimize products for a wide range of industries. Ginkgo Bioworks provide end-to-end capabilities for enzyme services, protein services, metabolic engineering services, strain optimization services, process design, and scale-up services as well as biosecurity services. It assists partners in producing sustainable agricultural solutions, high-quality plant-based meat, crucial vaccine components, and materials for eco-friendly fashion, among other innovations. 

Key customers and partnerships

In February 2022 , Ginkgo Bioworks collaborated with Phytolon to produce vibrant cultured food colors via the fermentation of yeast. The companies completed the first phase of this project and developed betalain pigments from specially engineered yeast strains, covering an extensive color range from yellow to purple. In June 2023 , the company partnered with Ambrosia Bio to use Ginkgo Enzyme Services, which include its proprietary chassis organisms, to create an expression strain for the scalable production of Ambrosia Bio's proprietary enzymes. These enzymes are instrumental in converting feedstock into allulose.

Funding and financials

The company began trading on the New York Stock Exchange from September 2021.

Ginko Biowork’s 2022 revenue increased 52% YoY to USD 477.7 million, compared to USD 313.8 million from 2021, driven by a 66% increase in Biosecurity revenue and a 27% increase in Foundry revenue. The company reported an EPS loss of USD 1.25 in 2022 versus a loss of USD 1.35 in 2021.

Ginkgo Biowork expects 2023 revenue of at least USD 275 million with Foundry revenue of at least USD 175 million and Biosecurity revenue of at least USD 100 million.